PT1957061E - Combinação compreendendo, pelo menos, um aminoácido e um inibidor de pkr para utilização no tratamento da perda muscular - Google Patents

Combinação compreendendo, pelo menos, um aminoácido e um inibidor de pkr para utilização no tratamento da perda muscular Download PDF

Info

Publication number
PT1957061E
PT1957061E PT06838457T PT06838457T PT1957061E PT 1957061 E PT1957061 E PT 1957061E PT 06838457 T PT06838457 T PT 06838457T PT 06838457 T PT06838457 T PT 06838457T PT 1957061 E PT1957061 E PT 1957061E
Authority
PT
Portugal
Prior art keywords
bcaa
amino acid
combination
muscle loss
treatment
Prior art date
Application number
PT06838457T
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Tisdale
Norman Alan Greenberg
Helen Eley
Kevin Burke Miller
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of PT1957061E publication Critical patent/PT1957061E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
PT06838457T 2005-11-30 2006-11-28 Combinação compreendendo, pelo menos, um aminoácido e um inibidor de pkr para utilização no tratamento da perda muscular PT1957061E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74109205P 2005-11-30 2005-11-30
US78094106P 2006-03-09 2006-03-09

Publications (1)

Publication Number Publication Date
PT1957061E true PT1957061E (pt) 2011-07-06

Family

ID=37806127

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06838457T PT1957061E (pt) 2005-11-30 2006-11-28 Combinação compreendendo, pelo menos, um aminoácido e um inibidor de pkr para utilização no tratamento da perda muscular

Country Status (17)

Country Link
US (1) US8329646B2 (https=)
EP (1) EP1957061B1 (https=)
JP (1) JP5260303B2 (https=)
CN (1) CN101316582A (https=)
AT (1) ATE508745T1 (https=)
AU (1) AU2006320670B8 (https=)
BR (1) BRPI0619179A2 (https=)
CA (1) CA2631647A1 (https=)
DK (1) DK1957061T3 (https=)
ES (1) ES2363442T3 (https=)
IL (1) IL191374A0 (https=)
MY (1) MY147489A (https=)
PT (1) PT1957061E (https=)
RU (1) RU2414897C2 (https=)
SG (1) SG163600A1 (https=)
WO (1) WO2007064618A1 (https=)
ZA (1) ZA200805657B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
DE102007016715A1 (de) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren
US20110077198A1 (en) * 2007-11-26 2011-03-31 Michael John Tisdale Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
CN101939011B (zh) 2008-02-07 2012-10-10 雀巢产品技术援助有限公司 用于影响由剧烈的体力活动中恢复的组合物和方法
US20090264363A1 (en) * 2008-03-26 2009-10-22 Ward Loren S Leucine-Rich Peptide Compositions and Methods for Isolation
US20130236447A1 (en) * 2008-12-23 2013-09-12 Carmel-Haifa University Economic Corp., Ltd. Cognitive function
US20120296403A1 (en) 2010-02-10 2012-11-22 Novartis Ag Methods and compounds for muscle growth
US20130330423A1 (en) * 2011-02-25 2013-12-12 Merck Patent Gmbh Composition to increase joint and/or postural stability
RU2454227C1 (ru) * 2011-04-05 2012-06-27 Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Композиция для восстановления скелетных мышц и кости при скелетной травме
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
CA2863809A1 (en) * 2012-02-06 2013-08-15 Ajinomoto Co., Inc. Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
US9700071B2 (en) 2012-03-26 2017-07-11 Axcella Health Inc. Nutritive fragments, proteins and methods
RU2634407C2 (ru) 2012-03-26 2017-10-26 Эксселла Хелт Инк. Фрагменты пищевых белков и способы их применения
EP2831098A4 (en) 2012-03-26 2016-12-07 Axcella Health Inc LOADED NUTRIENT PROTEINS AND METHODS
EP2831100A4 (en) 2012-03-26 2016-02-10 Pronutria Inc NUTRIENT PROTEINS AND METHOD
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
RU2517576C1 (ru) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Средство для профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой
ES2844199T3 (es) 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
HK1221609A1 (zh) * 2013-05-01 2017-06-09 Abbott Laboratories 增强老化肌肉再生的方法
CN103416760B (zh) * 2013-08-28 2014-09-10 山东卫康生物医药科技有限公司 治疗和预防肌肉衰减综合症的五谷杂粮全营养配方食品
RU2016110800A (ru) 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
KR101668074B1 (ko) * 2015-02-12 2016-10-21 전북대학교산학협력단 Ｐｋｒ 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물
CN105747214A (zh) * 2016-02-26 2016-07-13 四川安益生物科技有限公司 一种支链氨基酸组合物
JP7077235B2 (ja) * 2016-12-05 2022-05-30 大塚製薬株式会社 筋萎縮抑制組成物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
CN107440126A (zh) * 2017-09-08 2017-12-08 天津活力达生物科技有限公司 一种缓解运动疲劳的蛋白粉及其制备方法
EP3780973A4 (en) * 2018-04-18 2022-01-26 Ingenious Ingredients, LP COMPOSITIONS AND THEIR USE TO PROMOTE MUSCLE GROWTH AND FUNCTION
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
CA3143450A1 (en) * 2019-06-20 2020-12-24 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids
IT201900010437A1 (it) * 2019-06-28 2020-12-28 Dompe Farm Spa Composizione per il trattamento del deperimento muscolare

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
US4677121A (en) 1985-01-22 1987-06-30 The Johns Hopkins University Method of inhibiting muscle protein degradation
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
JPH03264525A (ja) * 1990-03-14 1991-11-25 Otsuka Pharmaceut Factory Inc アミノ酸輸液
US6608109B2 (en) 1991-11-20 2003-08-19 Allen Ann De Wees Composition comprising L-arginine as a muscle growth stimulant and use thereof
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US5817695A (en) * 1997-12-24 1998-10-06 Pellico; Michael A. Nutritional product with high fat, low carbohydrate and amino acid imbalance
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
MXPA01002173A (es) * 1998-08-28 2003-07-14 Scios Inc Inhibidores de p38-alfa cinasa.
US6051236A (en) * 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
CZ20022927A3 (cs) 2000-02-01 2003-06-18 Muscletech Research And Development Inc. Doplňky stravy založené na alfa-lipoové kyselině pro zvýšení čisté svalové hmoty a síly
US7199124B2 (en) * 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
FR2833012B1 (fr) 2001-12-04 2004-01-30 Centre Nat Rech Scient Peptides agonistes de l'hormone de croissance et leurs applications
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20080058324A1 (en) * 2004-08-25 2008-03-06 Santhera Pharmaceuticals (Schweiz) Ag Alpha-Keto Carbonyl Calpain Inhibitors
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
US7790688B2 (en) * 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly

Also Published As

Publication number Publication date
AU2006320670B8 (en) 2011-04-07
ZA200805657B (en) 2009-12-30
DK1957061T3 (da) 2011-07-25
ES2363442T3 (es) 2011-08-04
AU2006320670B2 (en) 2010-12-09
US20090105123A1 (en) 2009-04-23
EP1957061B1 (en) 2011-05-11
RU2414897C2 (ru) 2011-03-27
WO2007064618A8 (en) 2008-11-06
SG163600A1 (en) 2010-08-30
WO2007064618A1 (en) 2007-06-07
HK1118455A1 (en) 2009-02-13
AU2006320670A1 (en) 2007-06-07
CA2631647A1 (en) 2007-06-07
IL191374A0 (en) 2009-08-03
BRPI0619179A2 (pt) 2011-09-13
CN101316582A (zh) 2008-12-03
RU2008126294A (ru) 2010-01-10
JP5260303B2 (ja) 2013-08-14
JP2009517473A (ja) 2009-04-30
ATE508745T1 (de) 2011-05-15
MY147489A (en) 2012-12-14
EP1957061A1 (en) 2008-08-20
US8329646B2 (en) 2012-12-11

Similar Documents

Publication Publication Date Title
PT1957061E (pt) Combinação compreendendo, pelo menos, um aminoácido e um inibidor de pkr para utilização no tratamento da perda muscular
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
UA100111C2 (ru) Лечение диабета типа 2 комбинацией ингибитора dpiv и метформина или тиазолидиндиона
MY153198A (en) Inhibitors of protein aggregation
PL1898724T3 (pl) Preparat odżywczy dla niemowląt z hydrolizowanymi białkami
IL157821A0 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
MX2009005114A (es) Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
PH12014500685B1 (en) Treatment of degenerative joint disease
WO2007058990A3 (en) Therapy using cytokine inhibitors
IL194883A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
MX2009005946A (es) Combinacion de un inhibidor de desacetilasa de histona y un antimetabolito.
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
SE0401631D0 (sv) New Composition
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
ATE468849T1 (de) Idebenon zur behandlung von muskeldystrophien
MXPA05004920A (es) Combinacion que comprende un inhibidor cdk y cisplatin.
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
IS7899A (is) Samverkandi samsetning sem felur í sér róflúmílast og (R.R)-formóteról
NO20080464L (no) Terapeutisk kombinasjon omfattende en NMDA-reseptorhemmer og en narkotisk analgesisk substans
TW200640448A (en) Method and composition to inhibit infections with helicobacter pylori by intake of procyanidins from type B and C